[The use of interferon in the combined therapy of juvenile rheumatoid arthritis].
The efficacy of recombinant gene engineering alpha 2-interferon (reaferon) was studied and compared in 60 patients suffering from verified juvenile rheumatoid arthritis (JRA). Reaferon was shown to possess good tolerance and to produce an adequate therapeutic effect. The combined use of reaferon and methotrexate permits potentiating the therapeutic effect of interferon and avoiding side effects seen with methotrexate used alone. Besides, it makes it possible to reduce the incidence of respiratory infections which are often associated with exacerbation of the underlying disease when treated by conventional methods.
D000285:Administration, Rectal; D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000097:blood / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons / Q000097:blood / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011994:Recombinant Proteins; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007372:Interferons; D008727:Methotrexate
Ispol'zovanie interferona v kompleksnoĭ terapii iuvenil'nogo revmatoidnogo artrita.